Poor
Not Aligned
Patient Risk:
Low
Summary
Most statements are about atorvastatin-specific metabolism/interactions and general safety/timing; the provided PEPCID label excerpts do not support these claims. The only label-supported interaction concept provided is that famotidine can reduce absorption of other drugs via gastric pH and specifies certain drug classes (not atorvastatin/famotidine). Several safety/monitoring claims about atorvastatin are not supported by the PEPCID label excerpts.
Category Scores
Accurate Statements
Famotidine works by reducing stomach acid through an H2-receptor effect.
Section 12.1: "competitive inhibitor of histamine-2 (H2) receptors" and "inhibition of gastric secretion."
Timing may matter for other medications that depend on stomach pH for absorption.
Section 7.1: "Famotidine can reduce the absorption of other drugs, due to its effect on reducing intragastric acidity, leading to loss of efficacy of the concomitant drug."
With famotidine and atorvastatin, timing is usually not a major issue.
No supporting language in the provided label excerpts about atorvastatin or timing effects.
Famotidine is not typically a strong CYP3A4 inhibitor or inducer.
No CYP3A4 inhibition/induction statements in provided excerpts (only CYP1A2/tizanidine is discussed).
Unsupported Statements
There is no well-known, clinically important interaction between atorvastatin and Pepcid (famotidine).
The provided PEPCID label excerpts do not mention atorvastatin or any conclusion that there is no clinically important atorvastatin interaction.
Atorvastatin is metabolized mainly by liver enzymes.
Not addressed in the provided PEPCID label excerpts.
Atorvastatin is not driven by stomach-acid–driven pathways.
Not addressed in the provided PEPCID label excerpts.
The combination of atorvastatin and famotidine is generally considered safe in standard use.
The provided PEPCID label excerpts do not provide safety conclusions for atorvastatin/famotidine combination use.
Atorvastatin’s major metabolic route involves the CYP3A4 pathway.
Not addressed in the provided PEPCID label excerpts.
Medicines that affect the CYP3A4 pathway are typically considered when checking drug–drug interactions with atorvastatin.
Not addressed in the provided PEPCID label excerpts.
Transporters that can raise statin levels are typically considered when checking drug–drug interactions with atorvastatin.
Not addressed in the provided PEPCID label excerpts.
Famotidine is not typically a strong CYP3A4 inhibitor or inducer.
No CYP3A4 inhibition/induction information in provided excerpts; only CYP1A2 (tizanidine) is discussed.
Famotidine usually does not meaningfully increase atorvastatin exposure.
No atorvastatin exposure data or conclusions in provided PEPCID label excerpts.
When starting or changing doses of atorvastatin, patients should monitor for new or worsening muscle pain or weakness.
Atorvastatin-specific monitoring is not described in the provided PEPCID label excerpts.
When starting or changing doses of atorvastatin, patients should monitor for liver-related symptoms.
Atorvastatin-specific monitoring is not described in the provided PEPCID label excerpts.
Liver-related symptoms from atorvastatin are uncommon.
No atorvastatin adverse reaction frequency statements in the provided PEPCID label excerpts.
With famotidine and atorvastatin, timing is usually not a major issue.
No statement in provided PEPCID label excerpts about timing relevance for atorvastatin specifically.
The interaction strength between atorvastatin and famotidine can change with the exact Pepcid product (dose/form).
No atorvastatin/famotidine interaction strength statements in provided excerpts.
The interaction strength between atorvastatin and famotidine can change with the rest of the patient’s medication list.
While Section 7.1 describes drug absorption interactions broadly, the provided excerpts do not discuss interaction strength variability for atorvastatin/famotidine.
Contradictions
Low
AI Statement
The combination of atorvastatin and famotidine is generally considered safe in standard use.
Label Reference
Sections 7.1, 5, 6 (provided excerpts do not state this safety conclusion).
Important Omissions
If discussing drug-drug interactions with PEPCID, the label excerpts specifically identify interactions where concomitant administration is not recommended (dasatinib, delavirdine mesylate, cefditoren, fosamprenavir) and a specific interaction (tizanidine; avoid concomitant use).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The provided PEPCID label excerpts do not support most atorvastatin-focused claims; however, no direct PEPCID-label contradictions are present in the excerpts. Still, several unsupported interaction-safety statements could mislead interaction risk assessment.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Atorvastatin-specific metabolism/interaction claims and safety/monitoring guidance are not supported by the provided PEPCID label excerpts.
Suggested Improvement
Restrict interaction statements to what the PEPCID label excerpt supports (famotidine can reduce absorption of other drugs via reduced intragastric acidity; do not provide unsupported conclusions about atorvastatin interaction magnitude or safety). Include label-specified interaction cautions relevant to PEPCID (e.g., avoid concomitant use with tizanidine; not recommended with dasatinib/delavirdine mesylate/cefdioren/fosamprenavir as provided).